Over the last year I have been closely following the work of a group of very distinguished US clinicians who have developed the MATH+ Protocol, based on FDA approved medicines, to successfully treat Covid-19 patients. They have been using these repurposed medicines to achieve a 90% success rate for treating Covid-19 patients.
Launched in March the MATH+ Protocol consisted of:
Methylprednisolone and the antioxidant Ascorbic acid, which is given intravenously and in high doses. Both of these medicines have multiple synergistic physiologic effects and have been shown in multiple randomized controlled trials to improve survival in ARDS, particularly when given early in the disease. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. Given the numerous clinical and scientific investigations that have demonstrated consistent, reproducible, and excessive levels of hyper-coagulation, particularly in the severely ill, the anticoagulant Heparin is used to both prevent and help in dissolving blood clots that appear with a very high frequency.''
Now the MATH+ Protocol has been updated to include Ivermectin for both prophylactic and clinical use.
https://covid19criticalcare.com/wp-...CCC-I-MASK-Protocol-v5-2020-11-28-ENGLISH.pdf
Professor Paul Marik et al have recently published a meta-analysis of Ivermectin which has an astonishing efficacy as a prophylactic and for treating the different stages of Covid-19.
https://covid19criticalcare.com/wp-...the-prophylaxis-and-treatment-of-COVID-19.pdf
For a review of this meta analysis see this review by Dr. Chris Marttenson:
In their paper Marik et al comment on a new study that suggests Ivermectin can greatly benefit Covid Long Haulers.
Here is a quote from their paper on the use of Ivermectin as a treatment for Covid Long Haulers:
"Ivermectin in Post-COVID-19 Syndrome
Increasing reports of persistent, vexing, and even disabling symptoms after recovery from acute COVID-19 have been reported and which many have termed the condition as “long Covid” and patients as “long haulers”, estimated to occur in approximately 10% of cases (77–79). Generally considered as a post-viral syndrome consisting of a chronic and sometimes disabling constellation of symptoms which include, in order, fatigue, shortness of breath, joint pains and chest pain. Many patients describe their most disabling symptom as impaired memory and concentration, often with extreme fatigue, described as “brain fog”, and are highly suggestive of the condition myalgic encephalomyelitis/chronic fatigue syndrome, a condition well-reported to begin after viral infections, in particular with Epstein-Barr virus. Although no specific treatments have been identified for long COVID, a recent manuscript by Aguirre-Chang et al from the National University of San Marcos in Peru reported on the experience with ivermectin in such patients (80). They treated 33 patients who were between 4 and 12 weeks from the onset of symptoms with escalating doses of ivermectin; 0.2mg/kg for 2 days if mild, 0.4mg/kg for 2 days if moderate, with doses extended if symptoms Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
persisted. They found that in 87.9% of the patients, resolution of all symptoms was observed after two doses with an additional 7% reporting complete resolution after additional doses. Their experience suggests the need for controlled studies to better test efficacy in this vexing syndrome.''
Surely, this deserves greater publicity and action by public health authorities?
Launched in March the MATH+ Protocol consisted of:
Methylprednisolone and the antioxidant Ascorbic acid, which is given intravenously and in high doses. Both of these medicines have multiple synergistic physiologic effects and have been shown in multiple randomized controlled trials to improve survival in ARDS, particularly when given early in the disease. Thiamine is given to optimize cellular oxygen utilization and energy consumption, protecting the heart, brain, and immune system. Given the numerous clinical and scientific investigations that have demonstrated consistent, reproducible, and excessive levels of hyper-coagulation, particularly in the severely ill, the anticoagulant Heparin is used to both prevent and help in dissolving blood clots that appear with a very high frequency.''
Now the MATH+ Protocol has been updated to include Ivermectin for both prophylactic and clinical use.
https://covid19criticalcare.com/wp-...CCC-I-MASK-Protocol-v5-2020-11-28-ENGLISH.pdf
Professor Paul Marik et al have recently published a meta-analysis of Ivermectin which has an astonishing efficacy as a prophylactic and for treating the different stages of Covid-19.
https://covid19criticalcare.com/wp-...the-prophylaxis-and-treatment-of-COVID-19.pdf
For a review of this meta analysis see this review by Dr. Chris Marttenson:
In their paper Marik et al comment on a new study that suggests Ivermectin can greatly benefit Covid Long Haulers.
Here is a quote from their paper on the use of Ivermectin as a treatment for Covid Long Haulers:
"Ivermectin in Post-COVID-19 Syndrome
Increasing reports of persistent, vexing, and even disabling symptoms after recovery from acute COVID-19 have been reported and which many have termed the condition as “long Covid” and patients as “long haulers”, estimated to occur in approximately 10% of cases (77–79). Generally considered as a post-viral syndrome consisting of a chronic and sometimes disabling constellation of symptoms which include, in order, fatigue, shortness of breath, joint pains and chest pain. Many patients describe their most disabling symptom as impaired memory and concentration, often with extreme fatigue, described as “brain fog”, and are highly suggestive of the condition myalgic encephalomyelitis/chronic fatigue syndrome, a condition well-reported to begin after viral infections, in particular with Epstein-Barr virus. Although no specific treatments have been identified for long COVID, a recent manuscript by Aguirre-Chang et al from the National University of San Marcos in Peru reported on the experience with ivermectin in such patients (80). They treated 33 patients who were between 4 and 12 weeks from the onset of symptoms with escalating doses of ivermectin; 0.2mg/kg for 2 days if mild, 0.4mg/kg for 2 days if moderate, with doses extended if symptoms Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
persisted. They found that in 87.9% of the patients, resolution of all symptoms was observed after two doses with an additional 7% reporting complete resolution after additional doses. Their experience suggests the need for controlled studies to better test efficacy in this vexing syndrome.''
Surely, this deserves greater publicity and action by public health authorities?
![ME/CFS lecture | Dr Nancy Klimas | 2011 [Chronic Fatigue Syndrome / SEID / New Zealand] - YouTube](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
